Beyang Therapeutics Raises Nearly $30 Million for AI Drug Platform
Chengdu based Beyang Therapeutics has closed an oversubscribed Series A round raising nearly $30 million, the company said in a press release. The round was co led by Legend Capital and Shanghai Healthcare Capital, with participation from China Medical System Holdings, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners, and YuanBio Venture Capital.
Beyang said the funding will support updates to its ExCEED platform, which combines proprietary databases, AI, and computational simulation for molecular design, druggability optimization, and biological evaluation. The company also plans to use the proceeds for clinical and preclinical work on pipeline candidates and to expand international research and business teams.
The company said its BT01001 candidate is a small molecule eye drop for retinal diseases that has completed Phase I SAD and MAD studies in healthy subjects. Beyang is preparing patient trials for the therapy.
Beyang is also advancing BT01002, a second generation Menin inhibitor for KMT2Ar or NPM1 mutated acute leukemia. The candidate is in IND enabling studies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerce Nov 19 Spanish fintech Devengo raises €5 million for instant payments and AI agent transactionsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Atlas Bio raises $12.5 million for virtual drug trials
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Boltz raises $110 million to build AI models for drug design
Isomorphic Labs raises $5 billion Series C for AI drug design
BioMap Announces 11 AI Life Science Collaborations
Daily AI Brief: the AI news that matters, in your inbox.